PSMA-guided biopsy raised cancer detection in one trial
A single-center randomized study found more prostate cancers and fewer complications with a PET-guided robotic workflow, but it did not isolate the value of PET or establish a new standard of care.
The 60-second version
A single-center randomized trial found higher procedure-level cancer detection and fewer complications with a PSMA PET/CT-guided robotic biopsy workflow than with cognitive-fusion transrectal biopsy.
Key points
- The study randomized 217 biopsy-naive men with PI-RADS 4 or 5 MRI lesions: 112 to the PET pathway and 105 to the comparator.
- The headline detection result was 101/104 after PET-guided biopsy versus 85/105 in the comparison arm; eight PET-arm randomizations were outside the headline procedure denominator.
- Reported complications were 10.8% versus 51.4%, and median pain was 3 versus 5, but multiple parts of the biopsy workflow differed at once.
- The open-label, single-center pilot reported any prostate-cancer detection and does not establish routine PSMA PET screening or replacement of MRI.
Verdict. A strong signal worth multicenter confirmation, with intention-to-treat and clinically significant-cancer outcomes, before changing standard practice.
A single-center randomized trial found more prostate cancers with a gallium-68 PSMA-11 PET/CT-guided robotic biopsy workflow than with MRI cognitive-fusion transrectal ultrasound biopsy. It also reported fewer complications and less pain. The result is promising, but it compares two complete procedures in a selected population; it does not prove that PET alone produced the advantage or that routine care should change.
DesignWho was actually studied
The PROBIOP trial enrolled biopsy-naive men at one center in Chandigarh, India. The paper says participants were 50–90 years old, had PSA of at least 4 ng/mL and abnormal digital rectal examination findings, and all received multiparametric MRI.
Of 267 enrolled men, 217 had PI-RADS 4 or 5 lesions and were randomized. This was therefore not a general screening study: the analyzed population already had highly suspicious MRI findings for which targeted biopsy is ordinarily considered.
| PET-guided arm | 112 randomized; 104 received PSMA PET/CT-guided robotic biopsy and formed the headline detection denominator. |
|---|---|
| Comparison arm | 105 randomized to mpMRI cognitive-fusion transrectal ultrasound-guided biopsy. |
| Primary outcome | Detection of prostate cancer; the abstract does not separately headline clinically significant cancer. |
| Rescue pathway | PET-negative participants in arm 1 moved to cognitive-fusion biopsy; biopsy-negative participants in arm 2 received PET and PET-guided biopsy. |
ResultsThe signal was large, but the denominator matters
Cancer was found in 101 of 104 men who underwent PET-guided robotic biopsy, versus 85 of 105 in the cognitive-fusion arm. The reported rates were 97.1% and 81.0%, with P < 0.05. The PET-guided arm also had a higher proportion of positive tissue cores despite taking fewer cores.
For PI-RADS 5 lesions, the paper reports diagnostic accuracy of 100% versus 95.1%, but P = 0.09. That subgroup result is not statistically persuasive at the conventional 0.05 threshold and should not be presented as a proven difference.
SafetyFewer complications came with a different workflow
The authors reported complications in 10.8% of the PET-guided arm and 51.4% of the cognitive-fusion arm, with five major complications only in the latter. Median pain and procedure time were also lower in the PET-guided arm.
LimitsWhat the trial does not establish
- One center: local expertise and equipment may have amplified performance; multicenter replication is needed.
- Open-label pilot: participants and operators knew the assigned procedure, and the registry describes the study as a pilot.
- Selected patients: all randomized men had PI-RADS 4 or 5 lesions; the trial does not justify PSMA PET as a general PSA screening test.
- Outcome boundary: the abstract emphasizes detection of any prostate cancer, not a separately reported primary endpoint for clinically significant disease.
- Resource questions: radiation, tracer availability, robot access, cost and comparative cost-effectiveness were not resolved by the reported detection result.
- Incomplete reporting in the abstract: detailed adverse-event grades, pathology distribution and full intention-to-treat estimates require the complete paper and further studies.
A higher procedure-level detection rate is a reason for a larger trial, not by itself a new standard of care.
PracticeWhat patients and clinicians should do
For people already facing biopsy after a PI-RADS 4 or 5 MRI finding, the study supports asking whether targeted-biopsy options differ in route, anesthesia, infection risk, expertise, availability and cost. It does not show that MRI can be skipped, that biopsy is unnecessary, or that every elevated PSA should lead to PSMA PET. Clinical decisions should remain individualized with a urologist while larger multicenter evidence develops.